Recent studies have shown that expression of alternatively splicing variant
s of CD44 is correlated with prognosis for several kinds of malignant tumor
s. However, little is known about the expression of CD44 standard and varia
nt isoforms in soft tissue sarcomas. In this study 47 cases of soft tissue
sarcoma [18 malignant fibrous histiocytomas (MFHs), 13 synovial sarcomas (S
Ss), 7 malignant schwannomas (MSs), and 9 liposarcomas (LSs)] were examined
immunohistochemically. The monoclonal antibodies to the standard form of C
D44 (CD44H) and variant exons of CD44v3, 4, 5, 6, 7, 9, and v10 were used.
We analyzed the membranous expression pattern of CD44H and CD44 variant exo
ns and assessed the relation between expression of CD44s and metastasis-fre
e survival rates (MFSR) of patients with soft tissue sarcoma. A few sarcoma
s expressed CD44v3 (2/47) and v7 (2/47), but none of the sarcomas expressed
CD44v10. CD44v4 (5/47), v5 (4/47), v6 (10/47), and v9 (9/47) are relativel
y common types of variant isoforms in soft tissue sarcomas. Expression of C
D44v6 is more frequently detected in high-grade than in low-grade tumors. C
D44v6 or CD44v9 expression was correlated with metastasis-free survival of
patients with soft tissue sarcomas.